Search

(GLOBE NEWSWIRE via COMTEX) -- Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues [...]

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality was reported [...]

(GLOBE NEWSWIRE via COMTEX) -- First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) [...]

(GLOBE NEWSWIRE via COMTEX) -- First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video [...]

SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian [...]

(GLOBE NEWSWIRE via COMTEX) -- FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants - Nirsevimab would be the first immunization specifically designed to [...]

(GLOBE NEWSWIRE via COMTEX) -- Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting - HARMONIE Phase 3b data reinforce nirsevimab's consistent and high efficacy [...]

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('https://www.globenewswire.com/Tracker?data=85EhgJa8rCTOgcKgV8t4PsdLgtCfQDm2ays_0VxbL2UDQweGDjPCcgVO0uFLlfHEOHYBoLJyLt_rUDSXVkNGjA==') (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National [...]

(GLOBE NEWSWIRE via COMTEX) -- CHMP recommends approval of Beyfortus(R) (nirsevimab) for prevention of RSV disease in infants - Recommendation is based on the Beyfortus clinical trial program which demonstrated [...]

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug 08, 2022 (GLOBE NEWSWIRE via COMTEX) -- -- MET is the most common biomarker in patients with EGFR-mutated lung cancer [...]

SHANGHAI, China, Mar 17, 2022 (GLOBE NEWSWIRE via COMTEX) -- In a release issued under the same headline earlier today by Clover Biopharmaceuticals (Clover; HKEX: 2197), please note that in [...]

Phoenix, AZ, Mar 16, 2022 (GLOBE NEWSWIRE via COMTEX) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced the [...]

(GLOBE NEWSWIRE via COMTEX) -- Nirsevimab significantly protected infants against RSV disease in Phase 3 trial - Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV [...]

(GLOBE NEWSWIRE via COMTEX) -- - Study assesses impact of UV1 in ovarian cancer maintenance care - Addresses unmet medical need among BRCA-negative ovarian cancer patients - Enrollment of 184 [...]

CHENGDU, China, Nov 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- The Phase 2 trial will evaluate SCB-2019 (CpG 1018/Alum) as a booster dose in individuals previously vaccinated with CoronaVac [...]

HONG KONG and FLORHAM PARK, N.J., Nov 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Follows important findings from the TATTON study of the combination in EGFR inhibitor refractory lung [...]

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including [...]

Los Angeles, USA, Sep 14, 2021 (GLOBE NEWSWIRE via COMTEX) -- Ovarian Cancer Clinical Trials | A Drug Pipeline Analysis Report 2021 | DelveInsight Around 100+ key companies are developing [...]

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sep 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC ('AstraZeneca') (LSE/STO/Nasdaq:AZN) have initiated SANOVO, [...]

HONG KONG, SHANGHAI, FLORHAM PARK, Jul 27, 2021 (GLOBE NEWSWIRE via COMTEX) -- HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC ('AstraZeneca') (LSE/STO/Nasdaq: AZN) have initiated a Phase II [...]

(GLOBE NEWSWIRE via COMTEX) -- Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial - Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2 [...]

Dublin, June 16, Jun 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- The 'Market Spotlight: Gout' report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Gout market, [...]

KIGALI, May 28, 2021 (Xinhua via COMTEX) -- Rwanda will start the second phase of nationwide COVID-19 vaccination on Saturday, Rwanda Biomedical Center (RBC) said in a statement on Friday. [...]

KAMPALA, May 21, 2021 (Xinhua via COMTEX) -- Uganda on Friday started the second phase of COVID-19 vaccination in the country. Health minister Ruth Aceng, foreign minister Sam Kutesa and [...]

ACCRA, May 19, 2021 (Xinhua via COMTEX) -- Ghana on Wednesday commenced phase two of its mass vaccination against COVID-19 in 43 inoculation centers across the country. The health officials [...]

(GLOBE NEWSWIRE via COMTEX) -- Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial - Respiratory Syncytial Virus (RSV) is the leading cause of [...]

WASHINGTON, March 23, 2021 (Xinhua via COMTEX) -- Results from a U.S. trial of AstraZeneca's COVID-19 vaccine may have used 'outdated information,' a U.S. health agency said Tuesday, a day [...]

Byline: Sarah Boseley Mar 23, 2021 (The Guardian - ABIX via COMTEX) -- The independent Data & Safety Monitoring Board in the US has raised concerns about the validity of [...]

WASHINGTON, March 23, 2021 (Xinhua via COMTEX) -- Results from a U.S. trial of AstraZeneca's COVID-19 vaccine may have used 'outdated information,' a U.S. health agency said earlier Tuesday. The [...]

Dublin, March 11, Mar 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- The 'SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026' report has been added to ResearchAndMarkets.com's offering. This report [...]

SAN FRANCISCO, March 01, Mar 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action [...]

SAN FRANCISCO, Feb 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been [...]

Byline: Rachel Clun and Bevan Shields Jan 31, 2021 (The Age - ABIX via COMTEX) -- Phase-three clinical trials of the Novavax vaccine indicated that it has 89.3 per cent [...]

SAN FRANCISCO, Jan 28, 2021 (GLOBE NEWSWIRE via COMTEX) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud lawsuit has been filed [...]

Byline: Natasha Robinson Jan 14, 2021 (The Australian - ABIX via COMTEX) -- Professor Nikolai Petrovsky from the University of Adelaide has questioned the efficacy of AstraZeneca's COVID-19 vaccine. The [...]

MANILA, December 11, 2020 (Xinhua via COMTEX) -- AstraZeneca, the Britain-based drug maker, has withdrawn its application to conduct COVID-19 vaccine clinical trials in the Philippines, the country's Food and [...]

Dublin, Dec 01, 2020 (GLOBE NEWSWIRE via COMTEX) -- ResearchAndMarkets.com published a new article on the COVID-19 Vaccine industry 'AstraZeneca Likely to Run a New Global Trial of COVID-19 Vaccine' [...]

WASHINGTON, October 24, 2020 (Xinhua via COMTEX) -- Multinational pharmaceutical company AstraZeneca and U.S. pharmaceutical company Johnson & Johnson announced Friday that they would resume their phase 3 clinical trials [...]

MARSEILLE, France, Oct 23, 2020 (GLOBE NEWSWIRE via COMTEX) -- Milestone payment further bolsters Innate's cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients [...]

NEW DELHI, September 16, 2020 (Xinhua via COMTEX) -- The Drugs Controller General of India (DCGI) has ordered the Serum Institute of India (SII) to resume its phase 2 and [...]

Dublin, Sep 14, 2020 (GLOBE NEWSWIRE via COMTEX) -- ResearchAndMarkets.com published a new article on the clinical trials industry 'COVID-19 Antibody Treatment Clinical Trials' Pharmaceutical companies are investigating monoclonal antibodies [...]

MUMBAI, September 9, 2020 (Xinhua via COMTEX) -- An Indian company continues with its clinical trials for COVID-19 vaccine even as its partner AstraZeneca took a pause to the global [...]

WASHINGTON, September 1, 2020 (Xinhua via COMTEX) -- A multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222 has begun, the U.S. National Institutes of Health [...]

SAN FRANCISCO, Sep 01, 2020 (GLOBE NEWSWIRE via COMTEX) -- Headlands Research is pleased to announce that on Friday, Aug. 28, its JEM Research Institute clinical trial site in Lake [...]

Aug 25, 2020 (abc.net.au - ABIX via COMTEX) -- Some 20,000 people in the UK, Brazil and South Africa are participating in the stage-three clinical trial of Oxford University's coronavirus [...]

Aug 25, 2020 (abc.net.au - ABIX via COMTEX) -- Some 20,000 people in the UK, Brazil and South Africa are participating in the stage-three clinical trial of Oxford University's coronavirus [...]

SAN FRANCISCO, Aug 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- Headlands Research announced today that its research centers have been selected to participate in AstraZeneca's upcoming Phase III COVID-19 vaccine [...]

(GLOBE NEWSWIRE via COMTEX) -- Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial - Nirsevimab reduced respiratory syncytial virus (RSV) lower [...]

MARSEILLE, France, Mar 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ('Innate' or the 'Company') today announced that the first [...]

REHOVOT, Israel, Oct 28, 2019 (GLOBE NEWSWIRE via COMTEX) -- Dose-escalation study to determine maximum tolerated dose ahead of Phase 2 cohort expansion study Milestone marks initiation of studies in [...]